Cidara Therapeutics announced the appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development. In this position, Dr. Davarpanah will lead the company’s oncology efforts, focusing on the strategy for preclinical, translational, and early clinical development activities to identify and advance drug candidates through human proof-of-concept studies. Dr. Davarpanah joins Cidara from Genentech/Roche where she most recently served as Clinical and Translational Lead in Oncology.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CDTX:
- Cidara Therapeutics reports Q2 EPS (14c), consensus (13c)
- Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Cidara Therapeutics Provides Update on REZZAYO™ (rezafungin for injection)
- Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program
- Cidara Therapeutics provides update on status of CD388 program